BE634102A - - Google Patents
Info
- Publication number
- BE634102A BE634102A BE634102DA BE634102A BE 634102 A BE634102 A BE 634102A BE 634102D A BE634102D A BE 634102DA BE 634102 A BE634102 A BE 634102A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- headache
- hydantolne
- medicinal product
- dihydro
- Prior art date
Links
- 206010019233 Headaches Diseases 0.000 claims description 19
- 231100000869 headache Toxicity 0.000 claims description 19
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 14
- 229960001948 caffeine Drugs 0.000 claims description 9
- 239000008298 dragée Substances 0.000 claims description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940126601 medicinal product Drugs 0.000 claims description 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 229960004943 ergotamine Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE634102A true BE634102A (enExample) |
Family
ID=201326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE634102D BE634102A (enExample) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE634102A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6242488B1 (en) | 1997-08-20 | 2001-06-05 | University Of Oklahoma | Method for preventing and treating pain |
-
0
- BE BE634102D patent/BE634102A/fr unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242488B1 (en) | 1997-08-20 | 2001-06-05 | University Of Oklahoma | Method for preventing and treating pain |
| US6426368B2 (en) | 1997-08-20 | 2002-07-30 | Warner-Lambert Company | Method for preventing and treating alcoholism |
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6593368B2 (en) | 1997-09-08 | 2003-07-15 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6942876B2 (en) | 1997-09-08 | 2005-09-13 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11111202B2 (en) | Production of salts of 4-hydroxybutyrate using biobased raw materials | |
| US8859621B2 (en) | Pharmaceutical formulations of modafinil | |
| CA3199184A1 (en) | Mdma prodrugs to assist psychotherapy | |
| CN1929816A (zh) | 包含高浓度咪达唑仑的药用组合物 | |
| EP1646379A2 (fr) | Nouvelle composition pharmaceutique solide comprenant de l a misulpride | |
| WO1994012193A1 (fr) | Combinaison de cisplatine avec l'oxaliplatine | |
| JP6997995B2 (ja) | 中枢神経系及び脈管系障害の治療用のフェノール化合物及び、１，４－ジヒドロピリジンに融着したベンゾジアゼピンとのそれらの組合せ | |
| US11951086B2 (en) | Tablet or composition having n-acyl ethanolamine and cannabinoid | |
| BE634102A (enExample) | ||
| KR20250005055A (ko) | 아스피린 및 기타 nsaid의 고 침투성 전구약물을 이용한 심혈관 질환의 예방 또는 치료 | |
| US20250032520A1 (en) | Oral cannabinoid compositions and methods for treating neurological diseases and disorders | |
| RU2513580C1 (ru) | Средство для лечения аритмии сердца | |
| FR2758460A1 (fr) | Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants | |
| EP0108017A1 (fr) | Association renfermant à titre de principes actifs, un analgésique central et la vitamine B12 ou un de ses analogues | |
| BE1009851A3 (fr) | Composition pharmaceutique pour le traitement des cephalees et son utilisation. | |
| US12251361B2 (en) | Solutions for oral dosage | |
| EP3768321A1 (en) | Oral formulations of metronidazole and methods of treating an infection using same | |
| CH640137A5 (fr) | Composition pharmaceutique contenant de la s-adenosyl-l-homocysteine. | |
| CN114080221B (zh) | 用于减轻疼痛的布洛芬与曲马多的组合 | |
| CN109381466A (zh) | 促进糖尿病病人伤口愈合的治疗剂 | |
| FR2741532A1 (fr) | Nouvelles compositions pharmaceutiques a action antimigraineuse et leur mode de preparation | |
| FR2507891A1 (fr) | Medicament, notamment pour le traitement des maladies a virus du type herpes | |
| FR2691630A1 (fr) | Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1. | |
| RU2550916C1 (ru) | Фармацевтическая композиция для лечения заболеваний опорно-двигательного аппарата | |
| US20050182084A1 (en) | Method for treating erectile dysfunction |